Osteocalcin as a Potential Risk Biomarker for Cardiovascular and Metabolic Diseases

Clinical Chemistry and Laboratory Medicine - Germany
doi 10.1515/cclm-2015-0953
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Walter de Gruyter GmbH

Related search

Gamma-Glutamyl Transferase: Another Biomarker for Metabolic Syndrome and Cardiovascular Risk

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2007English

Rhodopsin: A Potential Biomarker for Neurodegenerative Diseases

Frontiers in Neuroscience
Neuroscience
2020English

Association Between Osteocalcin, Metabolic Syndrome, and Cardiovascular Risk Factors: Role of Total and Undercarboxylated Osteocalcin in Patients With Type 2 Diabetes

International Journal of Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2013English

Subcutaneous to Visceral Fat Ratio: A Possible Risk Factor for Metabolic Syndrome and Cardiovascular Diseases

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

Obesity as a Risk Factor for the Development of Cardiovascular Diseases

2019English

Cardiovascular and Metabolic Complications During Androgen Deprivation: Exercise as a Potential Countermeasure

Prostate Cancer and Prostatic Diseases
Cancer ResearchOncologyUrology
2009English

Can Telomere Length Be Used as a Biomarker for Cardiovascular Diseases? Insights From a Large Clinical Study

Journal of Physiology
PhysiologySports Science
2017English

Ghrelin as a Treatment for Cardiovascular Diseases

Hypertension
Internal Medicine
2014English

Microbial Risk Factors of Cardiovascular and Cerebrovascular Diseases: Potential Therapeutical Options

Open Neurology Journal
PsychiatryMental HealthNeurology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy